Sharda Cropchem Ltd
Sharda Cropchem is principally engaged in export of agrochemicals (technical grade and formulations) and non-agro products such as conveyor belts, rubber belts/sheets, dyes and dye intermediates to various countries across the world.
- Market Cap ₹ 8,058 Cr.
- Current Price ₹ 893
- High / Low ₹ 1,298 / 649
- Stock P/E 11.8
- Book Value ₹ 348
- Dividend Yield 1.01 %
- ROCE 30.4 %
- ROE 24.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 24.9% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 43.8%
Cons
- Company has a low return on equity of 13.6% over last 3 years.
- Company has high debtors of 166 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,061 | 1,222 | 1,399 | 1,707 | 1,998 | 2,003 | 2,396 | 3,580 | 4,045 | 3,163 | 4,320 | 5,268 | |
| 878 | 941 | 1,075 | 1,343 | 1,621 | 1,653 | 1,945 | 2,884 | 3,386 | 2,860 | 3,705 | 4,191 | |
| Operating Profit | 183 | 281 | 324 | 364 | 376 | 350 | 450 | 696 | 659 | 303 | 615 | 1,076 |
| OPM % | 17% | 23% | 23% | 21% | 19% | 17% | 19% | 19% | 16% | 10% | 14% | 20% |
| 25 | 23 | 14 | 9 | -22 | -12 | 46 | 29 | 40 | 60 | 60 | 106 | |
| Interest | 9 | 8 | 9 | 15 | 20 | 16 | 16 | 15 | 20 | 24 | 21 | 2 |
| Depreciation | 23 | 35 | 56 | 70 | 99 | 137 | 170 | 245 | 248 | 267 | 275 | 325 |
| Profit before tax | 175 | 261 | 272 | 287 | 235 | 185 | 309 | 464 | 431 | 72 | 378 | 856 |
| Tax % | 30% | 33% | 30% | 34% | 25% | 11% | 26% | 25% | 21% | 56% | 20% | 20% |
| 123 | 175 | 190 | 191 | 176 | 165 | 229 | 349 | 342 | 32 | 304 | 681 | |
| EPS in Rs | 13.63 | 19.41 | 21.11 | 21.14 | 19.55 | 18.25 | 25.40 | 38.71 | 37.90 | 3.53 | 33.74 | 75.47 |
| Dividend Payout % | 18% | 21% | 19% | 19% | 20% | 22% | 20% | 16% | 16% | 85% | 27% | 20% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 17% |
| 3 Years: | 9% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 25% |
| 3 Years: | 27% |
| TTM: | 128% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 20% |
| 3 Years: | 23% |
| 1 Year: | 38% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 15% |
| 3 Years: | 14% |
| Last Year: | 24% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 |
| Reserves | 564 | 715 | 870 | 1,045 | 1,194 | 1,313 | 1,524 | 1,822 | 2,142 | 2,147 | 2,410 | 3,046 |
| 38 | 2 | 0 | 170 | 0 | 0 | 81 | 47 | 3 | 18 | 8 | 0 | |
| 354 | 522 | 686 | 914 | 914 | 940 | 1,163 | 1,779 | 2,108 | 1,773 | 2,205 | 2,644 | |
| Total Liabilities | 1,047 | 1,329 | 1,646 | 2,219 | 2,198 | 2,343 | 2,858 | 3,738 | 4,343 | 4,028 | 4,713 | 5,780 |
| 88 | 130 | 210 | 226 | 372 | 416 | 544 | 592 | 668 | 708 | 750 | 1,236 | |
| CWIP | 149 | 210 | 232 | 360 | 220 | 161 | 131 | 212 | 204 | 283 | 291 | 0 |
| Investments | 95 | 90 | 61 | 22 | 212 | 116 | 83 | 134 | 32 | 159 | 294 | 361 |
| 715 | 899 | 1,143 | 1,611 | 1,394 | 1,650 | 2,099 | 2,800 | 3,439 | 2,878 | 3,377 | 4,183 | |
| Total Assets | 1,047 | 1,329 | 1,646 | 2,219 | 2,198 | 2,343 | 2,858 | 3,738 | 4,343 | 4,028 | 4,713 | 5,780 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 46 | 197 | 181 | 17 | 556 | 146 | 246 | 267 | 328 | 341 | 604 | 656 | |
| -19 | -113 | -104 | -160 | -351 | -59 | -282 | -205 | -112 | -393 | -496 | -513 | |
| -24 | -89 | -38 | 132 | -215 | -60 | 43 | -91 | -97 | -37 | -68 | -118 | |
| Net Cash Flow | 3 | -6 | 40 | -11 | -11 | 27 | 8 | -29 | 120 | -89 | 40 | 24 |
| Free Cash Flow | -34 | 196 | 39 | -185 | 413 | -30 | 15 | 33 | 84 | 69 | 211 | 158 |
| CFO/OP | 58% | 95% | 73% | 27% | 169% | 60% | 68% | 49% | 60% | 129% | 103% | 67% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 156 | 185 | 175 | 191 | 148 | 180 | 177 | 157 | 165 | 173 | 165 | 166 |
| Inventory Days | 72 | 74 | 117 | 169 | 96 | 100 | 117 | 130 | 145 | 155 | 117 | 121 |
| Days Payable | 117 | 179 | 186 | 202 | 167 | 180 | 180 | 172 | 176 | 144 | 158 | 162 |
| Cash Conversion Cycle | 111 | 81 | 106 | 158 | 77 | 100 | 114 | 115 | 134 | 184 | 124 | 125 |
| Working Capital Days | 82 | 95 | 99 | 94 | 71 | 101 | 94 | 88 | 97 | 128 | 92 | 127 |
| ROCE % | 27% | 36% | 32% | 27% | 23% | 18% | 21% | 26% | 21% | 4% | 16% | 30% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Product Registrations (Cumulative) Number |
|
||||||||||
| Annual Capital Expenditure (primarily for registrations) Rs. Crore |
|||||||||||
| Working Capital Cycle Days |
|||||||||||
| Number of Distributors Number |
|||||||||||
| Sales Force Strength Number |
|||||||||||
| Pending Registration Applications Number |
|||||||||||
| Agrochemical Volume Growth (Y-o-Y) % |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
19 May - Earnings Call Transcript of the conference call held on 14th May 2026.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 18 May
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
14 May - Submitted FY2026 Annual Secretarial Compliance Report; no material non-compliances reported.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
14 May - Audio Recording of Earnings Call Q4 FY 2025-26.
- Corporate Action-Board to consider Dividend 14 May
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
Concalls
-
May 2026Transcript PPT
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Jul 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT
-
Oct 2024Transcript PPT REC
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Jan 2024Transcript PPT
-
Oct 2023Transcript PPT
-
Jul 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Oct 2022Transcript PPT
-
Jul 2022Transcript PPT
-
May 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Oct 2021Transcript PPT
-
Jul 2021Transcript PPT
-
May 2021Transcript PPT
-
Jan 2021Transcript PPT
-
Oct 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jun 2020Transcript PPT
-
Jan 2020Transcript PPT
-
Oct 2019Transcript PPT
-
Jul 2019Transcript PPT
-
May 2019Transcript PPT
-
Jan 2019Transcript PPT
-
Oct 2018Transcript PPT
-
Jul 2018Transcript PPT
-
May 2018Transcript PPT
-
Jan 2018Transcript PPT
-
Oct 2017Transcript PPT
-
Jul 2017TranscriptPPT
-
May 2017Transcript PPT
-
Jan 2017Transcript PPT
-
Nov 2016Transcript PPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptAI SummaryPPT
-
Jan 2016Transcript PPT
Business Segments [1][2]
1) Agrochemicals: The company supplies formulations and generic active ingredients across the fungicide, herbicide, and insecticide segments. It also partners with third-party manufacturers to obtain completed formulations and generic active ingredients for resale. [3]